April 15, 2025

1 in 31: Autism Rate Hits New Mark

“The true or actual rate of autism [in the United States] is more likely to be closer to what this report has identified in California or Pennsylvania."

Reuters

April 14, 2025

Inebilizumab Effective for Myasthenia Gravis

CD19+ B-cell-depleting therapy shows significant improvement in function and disease severity in phase III trial of autoimmune neuromuscular disorder.

Conexiant

April 11, 2025

New Self-Injection Option for gMG, CIDP

A prefilled syringe version of VYVGART Hytrulo, which enables adult patients with generalized myasthenia gravis or chronic inflammatory demyelinating polyneuropathy to self-administer treatment in as little as 20 to 30 seconds, has been approved by the FDA.

Conexiant

April 10, 2025

September Deadline for Autism Etiology Findings

Federal initiative aims to pinpoint causes of rising autism rates by September, as HHS Secretary Kennedy launches global research effort.

Reuters

April 07, 2025

Cannabis for Pain: ACP Issues Best Practices

New guidelines from the American College of Physicians address the limited benefits and potential harms of cannabis and cannabinoids for chronic noncancer pain management.

Conexiant

April 02, 2025

Unequal Access Worsens Opioid Crisis for Black Patients

Despite rising opioid overdose rates among Black patients, systemic barriers and unequal access to treatment continue to hinder recovery efforts and worsen outcomes.

KFF Health News

April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 27, 2025

FDA Examines Stimulant Use Trends

The FDA reviews rising adult prescription stimulant use, ongoing shortages, and efforts to ensure appropriate access and minimize nonmedical use.

Conexiant